Animal models for muscular dystrophy: Valuable tools for the development of therapies

Human Molecular Genetics

Volumn 9, Issue 16 REV. ISS., 2000, Pages 2459-2467

  Allamand, V ^a   Campbell, K P ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; AMINOGLYCOSIDE; CAVEOLIN; CELL PROTEIN; COMPLEMENTARY DNA; DNA; DYSTROBREVIN; DYSTROGLYCAN; DYSTROPHIN; GENTAMICIN; GLYCOPROTEIN; INTEGRIN; MEROSIN; NITRIC OXIDE SYNTHASE; OLIGOMER; OLIGONUCLEOTIDE; PLASMID DNA; PROTEIN SUBUNIT; RNA; SARCOGLYCAN; UTROPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; DUCHENNE MUSCULAR DYSTROPHY; EXPERIMENTAL ANIMAL; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC ENGINEERING; GENETIC HETEROGENEITY; LABORATORY DIAGNOSIS; LIMB GIRDLE MUSCULAR DYSTROPHY; MOLECULAR GENETICS; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; TREATMENT PLANNING;

ANIMALIA; MURINAE;

EID: 0033758449     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/9.16.2459     Document Type: Review

References (143)

1. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals
2. Dystrophin: The protein product of the Duchenne muscular dystrophy locus
3. Association of dystrophin and an integral membrane glycoprotein
4. Glycoprotein complex anchoring dystrophin to sarcolemma
5. Membrane organization of the dystrophin-glycoprotein complex
6. Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl β-D-glucoside
7. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix
8. A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin
9. Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex
10. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy
11. Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies
12. Evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy
13. Caveolin-3 is not an integral component of the dystrophin glycoprotein complex
14. Dystroglycan: An extracellular matrix receptor linked to the cytoskeleton
15. Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage
16. Muscular dystrophies and the dystrophin-glycoprotein complex
17. From dystrophinopathy to sarcoglycanopathy: Evolution of a concept of muscular dystrophy
18. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy
19. β-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex
20. β-sarcoglycan: Characterization and role in limb-girdle muscular dystrophy linked to 4q12
21. Mutations in the dystrophin-associated protein γ-sarcoglycan in chromosome 13 muscular dystrophy
22. Primary adhalinopathy: A common cause of autosomal recessive muscular dystrophy of variable severity
23. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ-sarcoglycan gene
24. The sarcoglycan complex in limb-girdle muscular dystrophy
25. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms
26. Sarcoglycans in muscular dystrophy
27. Severe γ-sarcoglycanopathy caused by a novel missense mutation and a large deletion
28. The saga of congenital muscular dystrophy
29. Merosin and congenital muscular dystrophy
30. Mutations in the integrin α7 gene cause congenital myopathy
31. The molecular basis of muscular dystrophies
32. Molecular therapy for genetic muscle diseases-status 1999
33. The IVth workshop on Duchenne muscular dystrophy gene therapy
34. Therapies in muscular dystrophy: Current concepts and future prospects
35. Animal models of muscular dystrophies
36. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation
37. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice
38. New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin
39. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy
40. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy
41. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice
42. Expression of human full-length and minidystrophin in transgenic mdx mice: Implications for gene therapy of Duchenne muscular dystrophy
43. The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs
44. Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: A review
45. Identification of the Syrian hamster cardiomyopathy gene
46. Molecular pathogenesis of muscle degeneration in the δ-sarcoglycan-deficient hamster
47. Progressive muscular dystrophy in α-sarcoglycan-deficient mice
48. γ-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin
49. Loss of the sarcoglycan complex and sarcospan leads to muscular dystrophy in β-sarcoglycan-deficient mice
50. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy
51. Sarcoglycan isoforms in skeletal muscle
52. Disruption of the β-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E
53. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption
54. Sarcospan-deficient mice maintain normal muscle function
55. Laminin α2 chain-null mutant mice by targeted disruption of the Lama2 gene: A new model of merosin (laminin 2)-deficient congenital muscular dystrophy
56. Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models
57. Dystrophia muscularis: A hereditary primary myopathy in the house mouse
58. Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse
59. Murine muscular dystrophy caused by a mutation in the laminin α2 (Lama2) gene
60. Identification of a novel mutant transcript of laminin α2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice
61. Laminin in animal models for muscular dystrophy: Defect of laminin M in skeletal and cardiac muscles and peripheral nerve of the homozygous dystrophic dy/dy mice
62. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B
63. Dystrophic phenotype induced in vitro by antibody blockade of muscle α-dystroglycan-laminin interaction
64. Dystroglycan is essential for early embryonic development: Disruption of Reichert's membrane in Dag1-null mice
65. Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses
66. Absence of integrin α7 causes a novel form of muscular dystrophy
67. Dystrophic muscle in mice chimeric for expression of α5 integrin
68. Embryonic mesodermal defects in α5 integrin-deficient mice
69. Is myoblast transplantation effective?
70. The fate of individual myoblasts after transplantation into muscles of DMD patients
71. Successful myoblast transplantation in fibrotic muscles: No increased impairment by the connective tissue
72. Normal myoblast implantation in MDX mice prevents muscle damage by exercise
73. Prevention by anti-LFA-1 of acute myoblast death following transplantation
74. Development of approaches to improve cell survival in myoblast transfer therapy
75. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source
76. Dystrophin acts as a transplantation rejection antigen in dystrophin-deficient mice: Implication for gene therapy
77. Matching host muscle and donor myoblasts for myosin heavy chain improves myoblast transfer therapy
78. Partial laminin α2 chain restoration in α2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation
79. Myoblast transplantations lead to the expression of the laminin α2 chain in normal and dystrophic (dy/dy) mouse muscles
80. Muscle regeneration by bone marrow-derived myogenic progenitors
81. Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice
82. Dystrophin expression in the mdx mouse restored by stem cell transplantation
83. Blood borne macrophages are essential for the triggering of muscle regeneration following muscle transplant
84. Direct gene transfer into mouse muscle in vivo
85. The efficient expression of intravascularly delivered DNA in rat muscle
86. Muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression
87. Hypothesis: Naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process
88. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
89. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver
90. Implications of maturation for viral gene delivery to skeletal muscle
91. Muscle maturation: Implications for gene therapy
92. Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle
93. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
94. Next-generation adenoviral vectors: New and improved
95. Optimization of the helper-dependent adenovirus system for production and potency in vivo
96. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase
97. Developments in gene therapy for muscular dystrophy
98. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction
99. Genomic integration and gene expression by a modified adenoviral vector
100. Recombinant adeno-associated virus for muscle directed gene therapy
101. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
102. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
103. Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle
104. Replication-defective herpes simplex virus vectors for neurotrophic factor gene transfer in vitro and in vivo
105. Enhanced expression of recombinant dystrophin following intramuscular injection of Epstein-Barr virus (EBV)-based mini-chromosome vectors in mdx mice
106. Mini- And full-length dystrophin gene transfer induces the recovery of nitric oxide synthase at the sarcolemma of mdx4cv skeletal muscle fibers
107. Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice
108. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs
109. Primary structure of dystrophin-related protein
110. Calmodulin regulation of utrophin-actin binding
111. Utrophin: A structural and functional comparison to dystrophin
112. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene
113. Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice
114. Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice
115. Expression of full-length utrophin prevents muscular dystrophy in mdx mice
116. Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle
117. Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles
118. Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene
119. Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using δ-sarcoglycan gene transfer
120. Early adenoviral-mediated gene transfer effectively prevents muscular dystrophy in α-sarcoglycan-deficient mice
121. Rescue of skeletal muscles of γ-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer
122. Contrast agent-enhanced magnetic resonance imaging of skeletal muscle damage in animal models of muscular dystrophy
123. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector
124. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy
125. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy
126. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters
127. Cardiomyopathy in Duchenne, Becker, and sarcoglycanopathies: A role for coronary dysfunction?
128. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by β sarcoglycan mutations
129. The heart in limb girdle muscular dystrophy
130. Gene delivery to the myocardium by intrapericardial injection
131. Correction of genetic disease by making sense from nonsense
132. In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA-DNA oligonucleotide
133. Rescue of dystrophin expression in mdx mouse muscle by RNA-DNA oligonucleotides
134. Induction of utrophin gene expression by heregulin in skeletal muscle cells: Role of the N-box motif and GA binding protein
135. Activation of utrophin promoter by heregulin via the ets-related transcription factor complex GA-binding protein α/β
136. A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy
137. Immune response to adenovirus-delivered antigens upregulates utrophin and results in mitigation of muscle pathology in mdx mice
138. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
139. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line
140. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice
141. Aminoglycoside nephrotoxicity
142. Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: α-, β-, γ-, or δ-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vector